BluePrint
AgendiaThe BluePrint Molecular Subtyping Profile combined with the patient's MammaPrint test result, provides a greater level of clinical information to assist in therapeutic decision-making. BluePrint is an 80-gene expression signature which classifies breast cancer into Basal-type, Luminal-type and ERBB2-type cancers. An increasing body of evidence in the medical community suggests that breast cancer patients within these molecular…